ACITRETIN | A202148 | MYLAN PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Connetics Corporation - Citizen Petition FDA-2006-P-0451 · 10 docket documents Connetics Corporation filed this citizen petition in March 2006 under sections 505(b) and 505(j) of the Federal Food, Drug, and Cosmetic Act, requesting that the FDA withhold approval of any abbreviated new drug application for a generic version of acitretin capsules (Soriatane) until the applicant | 505(q) | 2008-07-14 | Partially Denied | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$3.59
per ea
Lowest NADAC/Unit
$2.14
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00378702393ACITRETIN 25 MG CAPSULE | $3.59 | EA | Generic | — | 2026-06-17 |
| 00378702093ACITRETIN 10 MG CAPSULE | $2.14 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.